Skip to Content


In the US, Dupilumab (dupilumab systemic) is a member of the drug class interleukin inhibitors and is used to treat Asthma - Maintenance, Atopic Dermatitis, Chronic Rhinosinusitis with Nasal Polyps and Eczema.

US matches:



CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Chemical Name

Immunoglobulin, anti-(human interleukin 4 receptor α) (human REGN668 heavy chain), disulfide with human REGN668 κ-chain, dimer (USAN)

Foreign Names

  • Dupilumabum (Latin)
  • Dupilumab (German)
  • Dupilumab (French)
  • Dupilumab (Spanish)

Generic Names

  • Dupilumab (OS: JAN)
  • REGN 668 (Stoffliste) (IS)
  • SAR 231893 (Stoffliste) (IS)
  • UNII-420K487FSG (ChemID) (IS)

Brand Names

  • Dupixent
    Regeneron, United States; Sanofi, Denmark; Sanofi, Ireland; Sanofi Oy, Finland; Sanofi-Aventis, Australia; Sanofi-Aventis, Netherlands; Sanofi-Aventis, Norway; Sanofi-Aventis, Poland


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.